XFOR
X4 Pharmaceuticals, Inc.
Healthcare — Biotechnology
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.
Price History
Fundamentals
| Market Cap | $375.39M |
| P/E Ratio (TTM) | - |
| Forward P/E | -4.85 |
| EPS (TTM) | $-2.05 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | -90.60% |
| ROE | -104.21% |
| Debt/Equity | 45.86 |
| Recommendation | None |
| Analyst Target | $11.60 |
| Analysts | 5 |
| Next Earnings | May 6, 2026 |
| Indexes | - |
Technical Indicators
| RSI (14) | 46.5 |
| Beta | 0.35 |
| SMA 20 | $3.93 |
| SMA 40 | $3.99 |
| 52-Week High | $4.83 |
| 52-Week Low | $1.35 |
| 50-Day Avg | $4.00 |
| 200-Day Avg | $3.86 |
| Avg Volume | 662.3K |
| Volume | 412.7K |
Performance Analysis
NEUTRALXFOR presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Aug 01, 2026 04:12 UTC
Back to Screener Export Report